Turning Point Therapeutics Inc logo

TPTX

Turning Point Therapeutics Inc

$76.01

Earnings Summary

Revenue
$0.43Mn
Net Profits
$-74.44Mn
Net Profit Margins
-17353.15%

Highlights

Revenue:

Turning Point Therapeutics Inc’s revenue fell -98.3% since last year same period to $0.43Mn in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 1602.04% jump in its revenue since last 3-months.

Net Profits:

Turning Point Therapeutics Inc’s net profit fell -109.68% since last year same period to $-74.44Mn in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 5.1% jump in its net profits since last 3-months.

Net Profit Margins:

Turning Point Therapeutics Inc’s net profit margin fell -12219.35% since last year same period to -17353.15% in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 94.42% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Turning Point Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.7
EPS Estimate Current Year
-1.7

Highlights

EPS Estimate Current Quarter:

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.7 - a -12.58% fall from last quarter’s estimates.

EPS Estimate Current Year:

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.7.

Key Ratios

Key ratios of the Turning Point Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.5
Return on Assets (ROA)
-0.14
Return on Equity (ROE)
-0.23
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Turning Point Therapeutics Inc’s earning per share (EPS) fell -105.48% since last year same period to -1.5 in the Q1 2022. This indicates that the Turning Point Therapeutics Inc has generated -105.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Turning Point Therapeutics Inc’s return on assets (ROA) stands at -0.14.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Turning Point Therapeutics Inc’s return on equity (ROE) stands at -0.23.

Dividend Per Share (DPS):

Turning Point Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-1.51
-1.5
0.66%

Company Information

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Organisation
Turning Point Therapeutics Inc
Headquarters
10628 Science Center Drive, San Diego, CA, United States, 92121
Employees
142
Industry
Biotechnology